申请人:Daiichi Pharmaceutical Co., Ltd.
公开号:US05681954A1
公开(公告)日:1997-10-28
A compound represented by formula (I): ##STR1## wherein Q represents an aryl group, a heterocyclic group, a diarylmethyl group, an aralkyl group composed of an aryl group and an alkylene group, an alkyl group or a cycloalkyl group, in which the aryl group, heterocyclic group, and the aryl moiety of the diarylmethyl group and aralkyl group may be substituted with one or more substituents; R represents a bicyclic, substituted, nitrogen-containing heterocyclic group or a substituted phenyl group, in which the nitrogen-containing heterocyclic group is composed of a 5-membered, substituted, aromatic or saturated ring containing one or two nitrogen atoms and a 6-membered ring; and Z represents an alkylene group, an alkenylene group, an alkylene group, a carbonyl group, an alkylene group containing a carbonyl group or an oxalyl group, or a salt thereof. The compound has calmodulin inhibitory activity and is useful as a treating agent for diseases in the circulatory organs or in the cerebral region which are caused by excessive activation of calmodulin.
化合物的化学式为(I):##STR1## 其中Q代表芳基,杂环基,二芳基甲基基团,由芳基和烷基组成的芳基烷基基团,烷基或环烷基,在其中,芳基,杂环基和二芳基甲基基团和芳基烷基基团的芳基部分可以被一个或多个取代基取代。R代表双环取代氮杂环基或取代苯基,其中氮杂环基由一个五元取代芳香或饱和环和一个六元环组成,其中含有一个或两个氮原子;Z代表烷基,烯基,含有羰基的烷基,含有羰基的烷基或草酰基,或其盐。该化合物具有钙调蛋白抑制活性,并可用作治疗循环器官或脑部区域疾病的治疗剂,这些疾病是由于钙调蛋白过度活化引起的。